Black Rock Inc. Corvus Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 562,024 shares of CRVS stock, worth $2.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

562,024

Previous 522,978 7.47%

Holding current value

$2.7 Million

Previous $930,000 9.89%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.36 - $2.29 $53,102 - $89,415	39,046 Added 7.47%	562,024 $1.02 Million
Q1 2024 May 10, 2024	BUY	$1.76 - $2.41 $4,271 - $5,849	2,427 Added 0.47%	522,978 $930,000
Q4 2023 Feb 13, 2024	SELL	$1.08 - $1.92 $756 - $1,344	-700 Reduced 0.13%	520,551 $916,000
Q3 2023 Nov 13, 2023	SELL	$1.41 - $2.97 $15,693 - $33,056	-11,130 Reduced 2.09%	521,251 $761,000
Q2 2023 Aug 11, 2023	BUY	$1.0 - $3.86 $39,159 - $151,153	39,159 Added 7.94%	532,381 $1.22 Million
Q1 2023 May 12, 2023	BUY	$0.65 - $0.92 $1,586 - $2,245	2,441 Added 0.5%	493,222 $448,000
Q4 2022 Feb 13, 2023	SELL	$0.74 - $1.04 $8,999 - $12,647	-12,161 Reduced 2.42%	490,781 $417,000
Q3 2022 Nov 14, 2022	SELL	$0.71 - $1.17 $1,863 - $3,070	-2,624 Reduced 0.52%	502,942 $411,000
Q2 2022 Aug 12, 2022	BUY	$0.87 - $2.03 $5,300 - $12,366	6,092 Added 1.22%	505,566 $501,000
Q1 2022 May 12, 2022	SELL	$1.46 - $2.48 $11,385 - $19,339	-7,798 Reduced 1.54%	499,474 $819,000
Q4 2021 Feb 10, 2022	BUY	$2.34 - $5.31 $951,961 - $2.16 Million	406,821 Added 404.99%	507,272 $1.22 Million
Q3 2021 Nov 09, 2021	SELL	$1.89 - $8.53 $57,601 - $259,968	-30,477 Reduced 23.28%	100,451 $486,000
Q2 2021 Aug 11, 2021	BUY	$2.46 - $3.14 $322,082 - $411,113	130,928 New	130,928 $350,000

Others Institutions Holding CRVS

# of Institutions

Shares Held

30.4M

Call Options Held

1.06M

Put Options Held

84.3K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account